Recombinant Mouse APITD1 Protein
Cat.No. : | APITD1-1772M |
Product Overview : | Recombinant Mouse APITD1 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
- Download
Source : | Mammalian Cells |
Species : | Mouse |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | Apitd1 apoptosis-inducing, TAF9-like domain 1 [ Mus musculus ] |
Official Symbol : | APITD1 |
Gene ID : | 69928 |
mRNA Refseq : | NM_027263.2 |
Protein Refseq : | NP_081539.1 |
MIM : | |
UniProt ID : | Q9D084 |
Products Types
◆ Recombinant Protein | ||
APITD1-621M | Recombinant Mouse APITD1 Protein, His (Fc)-Avi-tagged | +Inquiry |
APITD1-2307H | Recombinant Human APITD1 Protein, His-tagged | +Inquiry |
APITD1-4505C | Recombinant Chicken APITD1 | +Inquiry |
APITD1-7018Z | Recombinant Zebrafish APITD1 | +Inquiry |
◆ Lysates | ||
APITD1-8794HCL | Recombinant Human APITD1 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (20)
Ask a questionThe development of APITD1 may still be in its infancy, and more time and effort are needed to perfect it.
At present, the known indications and contraindications of APITD1 are not clear enough and require further study and evaluation.
The specific use method and dosage of APITD1 need to be determined according to the actual clinical situation, and it is best for doctors to guide the application.
The current clinical guidelines on APITD1 s may not be fully mature and require more research and clinical trials to develop.
At present, the patent status of APITD1 is not clear, and it is necessary to consult the relevant patent database to get accurate information.
Future directions of APITD1 may include more in-depth mechanism studies, expansion of clinical trials, and exploration of applications in multiple diseases.
The side effects of recombinant APITD1 are not fully understood, but with the use of any new drug, the potential risks generally need to be carefully evaluated. ⚠ ️
The APITD1 has the potential to be used in the treatment of various diseases, such as cancer and autoimmune diseases.
The APITD1 may need to be used in combination with other therapies, which needs to be evaluated and decided on a case-by-case basis.
The current research results on the APITD1 may still be ongoing and have not been fully published in academic journals. 📚
It is possible that relevant research institutions or laboratories are conducting research on APITD1 , but the specific situation needs to be further understood.
Regarding the safety of APITD1 in clinical trials, there are still insufficient research results, and further experiments and observations are needed.
At present, there are insufficient research results on the resistance of APITD1 , and further studies are needed to explore this.
The efficacy of APITD1 is generally determined through clinical trials and subsequent observational evaluation.
The academic community has some preliminary understanding of the mechanism and biological function of APITD1 , but further research is still needed.
It is not clear whether there are any products on the market that sell the APITD1 , but it is unlikely.
The APITD1 is usually administered by injection, as oral administration may not guarantee the stability and absorbability of the drug.
The mechanism of APITD1 is still being studied, but there are some preliminary studies that suggest it may play an important role in regulating immune response.
So far, clinical trials on APITD1 have been limited, but some preliminary studies suggest it may have potential.
There are some challenges in the study of APITD1, such as the stability of the drug, the determination of dosage and other issues to be overcome.
Customer Reviews (4)
Write a reviewThis green production method of APITD1 is not only conducive to environmental protection, but also brings long-term economic benefits to enterprises.
Short half-life and high clearance of APITD1 provide new ideas and methods for drug development, and it is expected to become a research hotspot in the field of biomedicine in the future.
Stability of APITD1 is very good, in a variety of application scenarios, no matter how the environment changes, it can maintain stable performance.
APITD1 performed very well in the experiment, and the results were reliable and reproducible.
Ask a Question for All APITD1 Products
Required fields are marked with *
My Review for All APITD1 Products
Required fields are marked with *
Inquiry Basket